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Abstract
Purpose: Exposure definitions vary across pharmacoepidemiological studies. There-
fore, transparent reporting of exposure definitions is important for interpretation of
published study results. We aimed to assess the quality of reporting of exposure to
identify where improvement may be needed.
Method:Wesystematically reviewed observational pharmacoepidemiological studies that
used routinely collected health data, published in 2017 in six pharmacoepidemiological
journals. Reporting of exposure was scored using 11 items of the ISPE-ISPOR guideline on
reporting of pharmacoepidemiological studies.
Results: Of the 91 studies included, all studies reported the type of exposure (100%),
while most reported the exposure risk window (85%) and the exposure assessment
window (98%). Operationalization of the exposure window was described infre-
quently: 16% (14/90) of the studies explicitly reported the presence or absence of an
induction period if applicable, 11% (5/47), and 35% (17/49) reported how stockpiling
and gaps between exposure episodes were handled, respectively, and 35% (17/49)
explicitly mentioned the exposure extension. Switching/add-on was reported in 62%
(50/81). How switching between drugs was dealt with and specific drug codes were
reported in 52 (57%) and 24 (26%) studies, respectively.
Conclusion: Publications of pharmacoepidemiological studies frequently reported the
type of exposure, the exposure risk window, and the exposure assessment window.
However, more details on exposure assessment are needed, especially when it con-
cerns the operationalization of the exposure risk window (eg, the presence or
absence of an induction period or exposure extension, handling of stockpiling and
gaps, and specific codes), to allow for correct interpretation, reproducibility, and
assessment of validity.
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1 | INTRODUCTION
Transparent reporting is important for interpretation of published study
results, but also for reproducibility and validity assessment. Reporting
guidelines support researchers to describe their research in a transparent
and complete manner, like CONSORT,1 for reporting on clinical trials,
STROBE,2 for reporting on observational studies, and STROBE-
RECORD,3 for reporting on observational studies using routinely col-
lected health data. These guidelines however do not capture the complex
operational details required for the conduct of pharmacoepidemiological
research, including complex exposure ascertainment algorithms.4
Recently, two guidelines were published that focus on these complex
operational details. The first is a guideline of a joint ISPE-ISPOR Task
Force,5 published in 2017 and the second an extension of the RECORD
statement, the RECORD-PE,4 published in 2018.
Both RECORD-PE and the joint ISPE-ISPOR Task-Force guide-
lines include a separate section on the reporting of the drug exposure
definition, with the latter most specific on operational details of expo-
sure ascertainment. Reporting details about the drug exposure defini-
tion is important, since drug exposure can be defined in various ways
in observational research, including time-fixed, time-varying, and
cumulative drug exposure definitions. In particular, regarding time-
varying definitions, researchers must make choices how the drug
exposure risk window is defined and how gaps or overlapping periods
between drug prescriptions or dispensings are being addressed when
constructing drug use episodes. As different choices may lead to dif-
ferent effects being estimated,6-9 it is important that researchers
report transparently how exposure was defined to aid correct inter-
pretation of results.
It takes a substantial amount of time to see the effects of publi-
shed guidelines on transparent reporting in practice. In the case of
CONSORT, reporting has improved in the 20 years after the first ver-
sion was published, but remains suboptimal, with on average 18 of 37
items being reported over the period of 2010-2014.10,11 Also in case
of STROBE, reporting has improved after publishing of the guideline,
but there is still room for improvement as the median compliance with
the 22 items is 77% in 2016, 9 years after STROBE was published.12
We therefore assessed the quality of exposure assessment reporting
according to ISPE-ISPOR Task Force Guidelines, in studies published
around the time frame where these guideline were published, to pro-
vide a baseline exposure assessment and to determine where
improvement may be needed.
2 | METHODS
To assess the quality of reporting of pharmacoepidemiological research,
we systematically reviewed observational pharmacoepidemiological
studies that used routinely collected health data. We used the guideline
by the ISPE-ISPOR Task Force to evaluate quality of reporting of expo-
sure, because this guideline aims to facilitate not only validity assessment
but also (direct) reproducibility, and therefore is most specific about
operationalization of the exposure riskwindow.
2.1 | Journal selection and eligibility of studies
We selected six pharmacoepidemiological journals: Annals of Pharma-
cotherapy, British Journal of Clinical Pharmacology, Drug Safety, Euro-
pean Journal of Clinical Pharmacology, Pharmacoepidemiology and Drug
Safety, and Pharmacotherapy. This selection of journals was based on
predefined criteria: at least 20 hits in 2017 that met the search crite-
rion in search of routinely collected health data. These 20 hits had to
cover at least 5% of the total publications of that specific journal and
the journal had to be classified in the category “Pharmacology and
pharmacy” at InCites Journal Citation Reports,13 with an impact factor
of at least 213 (details in file S1 in Data S1).
We included all of the studies published in 2017 in these six
journals that used routinely collected health data for exposure assess-
ment, such as prescription data, dispensing data or claims data. All
studies needed to include at least 250 subjects, to ensure that the
exposure assessment was not performed manually. Studies that used
questionnaires for exposure assessment were excluded. Studies
assessing vaccines were also excluded, as our interest was in reporting
of exposure that is used over a certain period of time, whereas vac-
cines are administered as single administrations.
2.2 | Extraction of study characteristics
The following general items were extracted: journal name, word count
limit of the article (≤1500 [short report], 1500-3000, 3000-4000 or
≥4000 words), study design (cohort, case-control, case-crossover or
other study design), the route of administration of the drug (oral/
inhaled or intravenous/subcutaneous), the type of outcome (beneficial
or adverse effect), the number of included subjects (categorized as
250-1000, 1001-10 000, 10 001-100 000 and >100 000 subjects),
KEY POINTS
• Transparent reporting of exposure definitions is impor-
tant for interpretation and reproducibility of published
study results.
• Publication guidelines, like RECORD-PE and the joint
ISPE-ISPOR guideline, provide guidance to researchers to
present their research in a transparent and complete
manner.
• This systematic review showed that publications of
pharmacoepidemiological studies frequently reported the
type of exposure, the exposure risk window, and the
exposure assessment window. However, more details on
exposure assessment are needed, especially when it con-
cerns the operationalization of the exposure risk window,
to allow for correct interpretation, reproducibility, and
assessment of validity.
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the type of database used for assessment of exposure (claims, General
Practitioner [GP], pharmacy or hospital database), and the geographi-
cal area where the study was conducted, defined as continents.
Because the ISPE-ISPOR guideline focuses on time-varying expo-
sure, we categorized the studies according to exposure definition in
five predefined categories (illustrated in Figure 1):
1 Intention to treat: drug exposure at baseline was included as a
time-fixed variable in the model.
2 The presence of ≥1 prescription during a certain period, for exam-
ple during pregnancy or during the last 12 months prior to the out-
come event of interest.
3 Time-varying: episodes of (non)exposure were constructed based
on duration of each prescription, without distinguishing between
different dosages.
4 Measures of adherence: for example, level of drug exposure was
measured as proportion of days a subject has drug in possession
divided by the total number of days of follow-up.
5 Dose and cumulative dose: drug exposure was modeled as a con-
tinuous or ordinal variable and the effects of different dosages at
index date were compared.
This categorization was carried out to notice any difference in
reporting between studies with different types of exposure defini-
tions. Characteristics of each included study were extracted indepen-
dently by two reviewers (M.H. and K.L.).
2.3 | Evaluation of reporting quality
Quality of reporting of exposure was assessed according to the ISPE-
ISPOR guideline.5 All items listed under “Section D – Reporting on expo-
sure definition” were assessed. Item D4 of the guideline contains four
elements (“Codes, frequency and temporality of codes, diagnosis posi-
tion and care setting”) and is linked with guideline section C (“Inclusion
and exclusion criteria”) for further clarification. In this section these items
F IGURE 1 Categorization of commonly used exposure definitions in pharmacoepidemiological studies. Different types of exposure definition are
applied in pharmacoepidemiological research.We divided these in five categories for further analysis: 1. intention to treat: exposure at baseline is included as
a time-fixed variable in themodel; 2. the presence of ≥1 prescriptions during a certain time period, for example during pregnancy or during the last 12 months
prior to the event; 3. time-varying: episodes of (non)exposure are constructed based on duration of each prescription; 4. measures of adherence: for example,
level of exposure ismeasured as proportion of days covered and 5. dose and cumulative dose: exposure ismodeled as a continuous or ordinal variable and
the effects of different dosages are compared (time-fixed or time-varying). DDD, daily defined dose; PDC, percentage of days covered; Rx, prescription
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are included as separate items, so we decided to split D4 into four sepa-
rate items as well. The item “diagnosis position (D4)” was excluded from
the final list of items as we considered this item not to be relevant for
drug exposures. The resulting 11 items are listed in Table 1.
To ensure uniform interpretation of the listed items when
assessing the articles, eight randomly chosen articles were reviewed
independently by two reviewers (M.H. and K.L.) and discrepancies of
the scores were discussed. This resulted in a formalized data extrac-
tion form that was used for the remaining articles.
Of each reviewed article, we scrutinized the methods sections
and, if referenced to, the supplementary materials for the data extrac-
tion. Each of the 11 items was scored as “not reported,” “reported,” or
“not applicable.” An item could be scored as “not applicable” if this
item was not relevant for that specific study. For example, if exposure
was defined as receiving 1 or more drug prescriptions, it was not rele-
vant to report how stockpiling and handling gaps were dealt with. The
items 3 (induction period, D2a) and 6 (exposure extension, D2d) (see
Table 1) could also be mentioned implicitly. For example, if an author
stated that “the follow-up started on the day of the first prescription
and ended after the duration of the last prescription,” it is implicit that
there was no induction period and no extension of the exposure risk
window. For items 3 and 6 we therefore also scored whether
reporting was “explicit” or “implicit.”
All articles were reviewed independently by two reviewers (M.H.
and K.L.) and discrepancies were discussed until consensus was
reached. The interobserver agreement (kappa) was 0.53. The eight
studies that were used to refine the assessment tool were excluded
from the calculation of the kappa.
In addition to the 11 ISPE-ISPOR items, we assessed whether the
exposure definition was accompanied by a figure for graphical repre-
sentation, since this is recommended in the ISPE-ISPOR guideline for
study design in general (item B1).
2.4 | Data analysis
For each of the ISPE-ISPOR reporting items, the primary outcomewas the
percentage of articles that reports this item, where applicable. The results
TABLE 1 Items pertaining to the quality of reporting of exposure definition in pharmacoepidemiological research. These items are selected
from the ISPE-ISPOR Joint Task Force guideline5
Item Explanation ISPE-ISPOR item
1. Type of exposure The type of exposure that is captured or measured, for example, drug
vs procedure, new use, incident, prevalent, cumulative,
time-varying.
D1
2. Exposure risk window (ERW) The ERW is specific to an exposure and the outcome under
investigation. For drug exposures, it is equivalent to the time
between the minimum and maximum hypothesized induction time
following ingestion of the molecule.
D2
3. Induction period Days on or following study entry date during which an outcome
would not be counted as “exposed time” or “comparator time.”
D2a
4. Stockpiling The algorithm applied to handle leftover days' supply if there are early
refills.
D2b
5. Bridging exposure episodes The algorithm applied to handle gaps that are longer than expected if
there was perfect adherence (eg, non-overlapping dispensation +
day's supply).
D2c
6. Exposure extension The algorithm applied to extend exposure past the days' supply for
the last observed dispensation in a treatment episode.
D2d
7. Switching/add on The algorithm applied to determine whether exposure should
continue if another exposure begins.
D3
8. Codes The exact drug, diagnosis, procedure, lab or other codes used to
define inclusion/ exclusion criteria.
D4
9. Frequency and temporality of codes The temporal relation of codes in relation to each other as well as the
study entry date (SED). When defining temporality, be clear
whether or not the SED is included in assessment windows (eg,
occurred on the same day, 2 codes for A occurred within 7 d of
each other during the 30 d prior to and including the SED).
D4
10. Care setting The restrictions on codes to those identified from certain settings, for
example, inpatient, emergency department, nursing home.
D4
11. Exposure assessment window (EAW) A time window during which the exposure status is assessed.
Exposure is defined at the end of the period. If the occurrence of
exposure defines cohort entry, for example, new initiator, then the
EAW may be a point in time rather than a period. If EAW is after
cohort entry, follow-up window must begin after EAW.
D5
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were stratified by study design, the number of patients included, the type
of outcome, the route of administration, the exposure definition, the type
of database used, and word limit of the article. The percentage of studies
that included a graphical presentation of the exposure definition was con-
sidered as a secondary outcome. In the case of multiple types of exposure,
designs or types of databases within one publication, we analyzed them as
one unit within the main analysis, including all information that was men-
tioned in the publication. For stratification purposes, we only used the
information provided for that specific design, exposure type or database.
3 | RESULTS
3.1 | Selection and characteristics of studies
A total of 91 articles were included (Figure 2, see file S2 for all refer-
ences in Data S2). The characteristics of all 91 articles are summarized
in Table 2. Different types of exposure were applied; 24 (26%) studies
performed an intention to treat analysis, 43 (47%) studies applied a
time-varying exposure assessment; 19 (21%) studies assessed the
occurrence of one or more prescriptions during a certain period, 4
(4%) used measures of adherence as exposure, and 3 (3%) investigated
the effect of (cumulative) dose. Two studies applied multiple defini-
tions in their study.
3.2 | Reporting quality
An average of 6.6 (SD 1.8) items were reported out of the 11 items per-
taining to quality of reporting of exposure definition. Themedian number
of items reported was 7, ranging between 2 and 10 per study. The
reporting of each item is presented in Table 3. Most studies reported the
type of exposure (eg, current use, cumulative dose) (n = 91, 100%), the
exposure risk window in general terms (n = 77, 85%), and the exposure
assessment window (n = 89, 98%). The operationalization of the expo-
sure window was infrequently described: of 90 studies that should
F IGURE 2 Flow chart of the
search and screening process to
select pharmacoepidemiological
studies using routinely collected
data. All articles published in
2017 in the following six journals
were included in the first step:
Annals of Pharmacotherapy,
British Journal of Clinical
Pharmacology, Drug Safety,
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report on an induction period, 14 (16%) studies explicitly reported the
presence or absence of an induction period, and another 67 (74%)
reported this implicitly. Among the 49 studies where exposure extension
was possible, 17 (35%) studies reported explicitly how long the exposure
was extended and 10 (20%) studies mentioned this implicitly. Stockpiling
and bridging of exposure episodes was reported in 5 of 47 (11%) and 18
of 44 (41%) studies. How switching between drugs or add-on was dealt
with was reported in 50 of 81 (62%) studies where this itemwas applica-
ble. Specific drug codes and care setting were reported in 24 of 91 (26%)
and 67 of 91 (74%) studies. Temporality of codes was reported in 77 of
91 (85%) studies.
Eleven studies (12%) supported the reporting of their exposure
definition with a graphical representation, nine of them in the article
itself and two in the supplementary materials.
3.3 | Stratification by study characteristics
The exposure definition determined which details needed to be
reported regarding the exposure assessment. Stratification by expo-
sure definition showed that studies using time-varying definitions
report on average more items compared with all other definitions (7.4
(SD 1.7) vs 6.0 (SD 1.7), Table S1 in Data S3). The items stockpiling
(item 4) and handling gaps (item 5) were considered to be relevant
only for the time-varying definitions, where they were reported in 7%
and 42% of the studies respectively. Exposure extension (item 6) was
also reported more often in the studies with a time-varying exposure
assessment (42%) vs studies with another exposure definition (6%).
TABLE 2 Characteristics of the studies included for evaluation of
quality of reporting of pharmacoepidemiological studies (n = 91)
n (%)
Journal
Annals of Pharmacotherapy 7 (8)
British Journal of Clinical Pharmacology 16 (18)
Drug Safety 8 (9)
European Journal of Clinical Pharmacology 17 (19)







Beneficial effects 18 (20)
Adverse effects 67 (74)
Beneficial and adverse effects 6 (7)
Number of subjects included
250-1000 13 (14)
1001-10 000 30 (33)
10 001-100 000 24 (26)
>100 000 24 (26)
Type of databasea
Claims database 41 (44)
GP database 17 (19)
Hospital database 18 (20)





North America 36 (40)
Australia 2 (2)
Route of administration
Oral and inhaled 80 (88)
Intravenous and subcutaneous 11 (12)
Exposure definitiona
Intention to treat 24 (26)
≥1 prescription/dispense during a certain period 19 (21)
Time-varying 43 (47)
Measures of adherence 4 (4)
(Cumulative) dose at index date 3 (3)
aSum of n may exceed 91.
TABLE 3 Quality of Reporting of exposure for the included
studies. For each specific item, the number of studies reporting that






1. Type of exposure 91 91 (100)
2. Exposure risk window (ERW) 91 77 (85)
3. Induction perioda 90 81 (90)
Explicit 14 (16)
Implicit 67 (74)
4. Stockpiling 47 5 (11)
5. Bridging exposure episodes 44 18 (41)
6. Exposure extensiona 49 27 (55)
Explicit 17 (35)
Implicit 10 (20)
7. Switching/ add on 81 50 (62)
8. Codes 91 24 (26)
9. Frequency and temporality of
codes
91 77 (85)
10. Care setting 91 67 (74)
11. Exposure Assessment Window
(EAW)
91 89 (98)
aWhen explicitly mentioning an induction period, a period after the index
date is clearly excluded in the exposure risk window. Stating that follow-
up started on the day of the first prescription implies implicitly that there
was no induction period. The same reasoning applies to the extension
period.
bTotal number of studies to which this item was applicable.
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TEXTBOX 1 Examples of good practices for each of the items in the ISPE-ISPOR checklist cited from included articles
1. Type of exposure “Those who filled a prescription for an antidepressant during this period <1 January 2007 and 31
December 2013> with no such fills during the preceding year were considered treatment
initiators.”23
“In the first model, the mutually exclusive binary indicators of use for each NSAID were (a) current use on
the index date, (b) recent use 1 to 30 days ago, (c) past use 31 to 180 days ago, or (d) no use in the last
180 days before the index date.”24
2. Exposure risk window
(ERW)
“For each patient, we defined a period of continuous drug use beginning with the first prescription after
their 66th birthday and ending with death, discontinuation of treatment, the end of the study period
(31 March 2014), or 90 days of follow-up, whichever occurred first. <…> We based our selection of a
90-day observation window on existing literature describing heart failure and edema within a few
months of pregabalin therapy.”25
“The primary outcome was hospitalization for COPD or pneumonia within 30 days after the index date
<…>”26
3. Induction period “<…> the effect of insulin on chronic complications may take some time, so we conducted a lag-time
analysis, whereby patients with chronic complication events that occurred 3 years after the initiation of
insulin were excluded.”27
“Outcomes were collected starting 30 days following the index date to ensure that events occurring
during the baseline period were not mistakenly captured as study period events.”28
4. Stockpiling “For overlapping prescriptions, the individual was assumed to have completed the former one before
starting the second.”29
“To account for gaps and overlaps in redemptions due to incomplete adherence or lost prescriptions, we
presumed that health-insured persons have drug stocks lasting up to 15 days due to incomplete
compliance (‘15- day rule’), added apparent overlaps up to a maximum overlap duration corresponding
to 25% of the quantity of the last overlapping prescription, and applied common recommendations to
fill apparent gaps between prescriptions using prospective filling.”30
5. Bridging exposure episodes “Discontinuation of use <was> defined as a 60-day gap between the end of one COC prescription and the
next COC prescription”31
6. Exposure extension “Observation was extended by half the days supplied from the final prescription to capture outcomes that
may have prompted cessation of therapy”25
7. Switching/ add on “If a patient switched from warfarin to rivaroxaban or vice versa during the study period, that was
considered discontinuation of the index drug, and they were censored at that time.”32
“To assess whether associations varied with different antidepressants, we categorized antidepressants
into 3 types (SSRI monotherapy, non-SSRI monotherapy, or both SSRI and non-SSRI
antidepressants).”33
8. Codes “Antihypertensive drugs studied were: angiotensin-converting enzyme (ACE) inhibitors: ATC code C09A
and C09B, angiotensin receptors blockers (ARBs): ATC code C09C and C09D, calcium channel blockers
(CCBs): ATC code C08, β-blockers: ATC code C07, diuretics: ATC code C03 (thiazide or thiazide-like
diuretics, loop diuretics and potassium-sparing diuretics) and miscellaneous antihypertensive agents:
ATC code C02.”34
“We selected all patients who had ever received Fz/Cz <…> according to the Anatomical Therapeutic
Chemical (ATC) codes N07CA03 (for Fz) and N07CA02 (for Cz) <…>.”35
9. Frequency and temporality
of codes
“All patients included in the Cohort were followed from the 90th day after the incident ACS occurrence
(index date) until the incidence of a major adverse cardiac event (MACE), death, date removed from the
database or 31 December 2013, whichever came first.”36
10. Care setting “Because of the high patient pharmacy loyalty in the Netherlands, the prescription records for each




“As diagnosis and treatment start may be registered in different days <…>, we allowed a time interval of
±3 months from diagnosis date and start of treatment.”38
“We conducted a <study of residents> prescribed digoxin at any time between 1 January 1994 and 31
December 2012, the last date for which complete data were available.”39
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Stratification by route of administration also showed differences,
studies on intravenous or subcutaneous administered drugs reported
less frequently on nearly all items than studies on oral or inhaled drugs.
Stratification by study design, number of subjects included in the
study, type of outcome, type of database used, and word limit of the
article, did not reveal major differences. The results of the stratified
analyses are available in the file S3, Tables S1-S7 in Data S3.
4 | DISCUSSION
This systematic review of quality of reporting of drug exposure in
pharmacoepidemiological studies showed that none of the studies
assessed met all requirements of reporting of drug exposure as
defined by the ISPE-ISPOR guideline. The number of reported items
varied widely between studies, ranging from 2 to 10. In general, the
conceptual details about the exposure risk window and the exposure
assessment window were reported relatively often (85% and 98%,
respectively). However, the operational details concerning the con-
struction of the exposure risk window were reported less often. For
example, handling gaps and overlapping episodes were reported in
only 11% and 41% of studies, where this type of reporting was appli-
cable, thereby impeding reproducibility.
Our findings on the substandard quality of reporting of
pharmacoepidemiological database studies are in linewith the results of a
study by Wang et al.14 In their attempt to reproduce 31
pharmacoepidemiological database studies, they noted that code lists for
outcomes, covariates and inclusion/exclusion criteria were reported in
only 11 of 31 studies (35%). Likewise, we found that code lists for drug
exposure were only reported in 24 of 91 studies (26%). Although not all
details were reported, Wang et al were able to reproduce several data-
base studies with high accuracy, but mention that this was partly due to
“the efforts of the reproduction team, a group of pharmacoepidemiologists
with decades of experience, tomake informed guesses regarding variable defi-
nitions or other key decisions when these were not clearly specified in the
original articles.”14 It is debatable whether this level of expertise could be
expected from the general reader of pharmacoepidemiological studies.
Therefore, it is important that details are reported clearly for correct inter-
pretation and reproducibility of study results.
Besides reporting operational details, it is important to clearly describe
the choices regarding the exposure definition, such as the exposure risk
window and what type of exposure is examined. Currently there are a
number of guidelines to support these methodological choices, like the
ISPE Guidelines for good pharmacoepidemiology practices,15 the ENCePP
Guide onMethodological Standards in Pharmacoepidemiology,16 the FDA
guidance for Conducting and Reporting Pharmacoepidemiologic Safety
Studies Using Electronic Healthcare Data,17 the User's Guide for Develop-
ing a Protocol for Observational Comparative Effectiveness Research by
the Agency for Healthcare Research and Quality,18 and the EU Good
Pharmacovigilance Practice (Module VIII).19 Without clear reporting of all
key decisions, assessment of the validity of the results will be difficult.
A strength of this study was the independent assessment of all
studies by two researchers. This also revealed one of the limitations of
this study: substantial interpretation was needed by the researchers to
score all studies, which is also reflected in a moderate kappa of 0.53.
This could partially be explained by the fact that not all questions of
the checklist applied to each study included in our study. The listed
guideline items could be scored most easily for a study design with
time-varying treatment episodes. The items 4 (stockpiling, D2b), 5 (han-
dling gaps, D2c), 6 (exposure extension, D2d) and 7 (switching, D3)
were for other types of exposure, (eg, intention to treat) not relevant
and thus scored NA. This is also reflected in the kappa and the percent-
age agreement of these items (file S4 in Data S4). When we rec-
alculated kappa, with only a contrast between reporting something
(Yes) or not (No or NA), this resulted in a kappa of 0.64.
There was also a difference between the reporting of exposure to
drugs that were oral or inhaled administered, compared with the
reporting of exposure drugs that were intravenous or subcutaneous
administered. This might be explained by the fact that intravenous or
subcutaneous drugs are commonly identified by procedural codes
instead of drug dispensing information. These data contain other
information about the drug exposure, resulting in also another way of
reporting of the drug exposure assessment, which might not be cap-
tured in the guideline used for this review.
Another possible limitation concerns the inclusion of only publica-
tions in six pharmacoepidemiological journals. The results may thus
not be generalizable to the quality of reporting of drug exposure in
general. Furthermore, we only searched the methods and supplemen-
tary materials (if referenced) for exposure assessment information,
possibly missing out on information described in other sections of the
publication. For transparency reasons, it is however still rec-
ommended to describe all methodological choices in the methods sec-
tion. In addition, it might also be possible that these details are
described in other study reports, such as reports provided to the regu-
lator, but are left out of the publication, due to word count limitations.
We did, however, not see differences in results between publications
in journals with a strict word limit (≤3000 words) compared to publica-
tions in journals with less stringent word limits.
Suboptimal reporting is not unique to pharmacoepidemiological
research and the effort for more transparent reporting has facilitated
the development of various reporting guidelines, such as CONSORT
and STROBE. To further stimulate use of these, endorsement by many
journals has resulted in improved reporting, but after two decades,
adherence to CONSORT is still suboptimal.20-22 In order to accelerate
adherence to RECORD-PE and the ISPE-ISPOR guideline, it might be
considered to oblige authors to use one of these two guidelines. Four
of the six included journals (Annals of Pharmacotherapy, British Journal
of Clinical Pharmacology, Drug Safety, Pharmacoepidemiology and Drug
Safety) currently recommend authors to adhere to the guidelines avail-
able through the EQUATOR network, including the RECORD-PE
guideline. One journal (European Journal of Clinical Pharmacology)
advises to adhere to CONSORT for observational research and one
journal (Pharmacotherapy) does not recommend a specific reporting
guideline. In addition, current good practices can be used as examples.
We summarized some good practices of clear reporting of exposure
assessment in Textbox 1, which can be helpful for future studies. We
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also noticed that giving arguments for specific choices was helpful for
the interpretation of the conceptual choices, as was the inclusion of a
graphical representation for the interpretation of the operational
choices.
To conclude, we recommend that publications of pharmaco-
epidemiological studies should include more details on exposure ascer-
tainment, especially about the operationalization of the exposure risk
window (eg, the presence or absence of an induction period or exposure
extension, handling of stockpiling and gaps, and specific codes), to allow
correct interpretation of the results and to enable reproducibility, and
validity assessment. Authors, reviewers, and editors are encouraged to
paymore attention to adhere to relevant reporting guidelines such as the
ISPE-ISPOR and RECORD-PE guidelines.
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